Molecular Status of Braf Mutation in Prostate Adenocarcinoma: the Analysis of 100 Cases in North-East of Iran

Background and objective: braf mutations were studied in various populations for prostate carcinoma (pc); however, mutations in braf gene are unusual compared to kras. oncogenic activating of braf mutations were studied lately in almost 0%- 10% of prostate cancer cases. methods: in this retrospective study, we gathered 100 formalin-fixed paraffin-embedded samples of prostate adenocarcinoma. a hundred archived samples of adjacent benign prostatic hyperplasia were chosen as normal control. this study was done in pathology laboratory of qaem hospital during 2013-2015. results: total number of 200 pc and normal cases was investigated for braf v600e mutation. the braf v600e mutation was found in only 4 patients but it was not detected in normal cases. there were no significant differences between patient and control groups for this mutation (p>0.99). the frequency of braf v600e mutation was not significant in different age groups (p>0.285); the most frequency was related to the age range of 71-80. no significant difference was observed between tumor grade and braf mutation (p=0.21). conclusion: according to our findings, braf gene mutations did not play essential role in pc. therefore, anti-braf (v600e) could not be considered as a proper target for therapy.